USFDA completes inspection at Cipla’s API manufacturing facility in Bengaluru

20 Jul 2019 Evaluate

US Food and Drug Administration (USFDA) has completed a routine cGMP inspection at Cipla’s API manufacturing facility in Virgonangar, Bengaluru. The inspection ended with 7 observations, none of which were repeat or related to data integrity. The inspection had conducted from June 15, 2019 to June 19, 2019.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.

Cipla Share Price

1406.45 49.50 (3.65%)
15-May-2024 15:13 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1526.85
Dr. Reddys Lab 5874.00
Cipla 1406.45
Zydus Lifesciences 998.00
Lupin 1638.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.